SG11201805092WA - Cortistatin analogs and uses thereof - Google Patents

Cortistatin analogs and uses thereof

Info

Publication number
SG11201805092WA
SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA
Authority
SG
Singapore
Prior art keywords
international
mpk
quincy
president
cambridge
Prior art date
Application number
SG11201805092WA
Inventor
Matthew Shair
Henry Pelish
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG11201805092WA publication Critical patent/SG11201805092WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMIOH0110101011111 HO 11111011101110111 011111111011110111111011011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/112815 Al 29 June 2017(29.06.2017) WIPO I PCT (51) International Patent Classification: C07D 519/00 (2006.01) C07K 16/26 C07D 493/08 (2006.01) (21) International Application Number: (22) International Filing Date: 21 December (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/387,246 23 December 2015 (23.12.2015) 62/297,494 19 February 2016 (19.02.2016) (71) Applicant: PRESIDENT AND FELLOWS VARD COLLEGE [US/US]; 17 MA 02138 (US). (72) Inventors: SHAIR, Matthew, D.; lows of Harvard College, 17 Quincy MA (US). PELISH, Henry, Efrem; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US2016/068125 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 2016 (21.12.2016) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, English ZA, ZM, ZW. English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, OF HAR- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Quincy St, Cambridge, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). c/o President and Fel- Street, Cambridge, Declarations under Rule 4.17: c/o President and Fel- - as to applicant's entitlement to apply for and be granted a Street, Cambridge, patent (Rule 4.17(ii)) — as to the applicant's entitlement to claim the priority of the al.; Knowles Intellectu- earlier application (Rule 4.17(iii)) Center Terrace Published: indicated, for every — with international search report (Art. 21(3)) AE, AG, AL, AM, — lows of Harvard College, 17 Quincy — MA (US). = (74) Agents: BELLOWS, Brent, R. et Property LLC, 400 Perimeter al Strategies, NE, Suite 200, Atlanta, GA 30346 (US). (81) (unless otherwise Designated States = kind of national available): protection = USES THEREOF .4. vehicle .0.. F 1 mpk PO CA 0.16 mpk IP -4- B It) mpk PO = (54) Title: CORTISTATIN ANALOGS AND = = = = GI 0 = .61 32768 .. = .0 16384 . _ c 8192 . = 4096 2048 0 0 go 1024 _ c„) 512 _ 0 eD 256 .9 128 C 5 mpk PO -is. D 3nips; IV 1-1 & ir) 1 3 6 9 1.2 15 ,-1 Treatment days GC ei 11 FIG. 31 11 IN 1-1 (57) : Specific Cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, N in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hERG activ - ity, and/or other pharmacological properties which make them stand out among the class of Cortistatins as superior candidates for 0 human administration.
SG11201805092WA 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof SG11201805092WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387246P 2015-12-23 2015-12-23
US201662297494P 2016-02-19 2016-02-19
PCT/US2016/068125 WO2017112815A1 (en) 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof

Publications (1)

Publication Number Publication Date
SG11201805092WA true SG11201805092WA (en) 2018-07-30

Family

ID=59091204

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805092WA SG11201805092WA (en) 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof

Country Status (17)

Country Link
US (1) US20180298024A1 (en)
EP (1) EP3394072A4 (en)
JP (1) JP2019508368A (en)
KR (1) KR20180095051A (en)
CN (1) CN108699085A (en)
AU (1) AU2016377678A1 (en)
BR (1) BR112018012647A2 (en)
CA (1) CA3009324A1 (en)
CL (1) CL2018001733A1 (en)
CO (1) CO2018007535A2 (en)
EA (1) EA201891511A1 (en)
IL (1) IL260123A (en)
MX (1) MX2018007804A (en)
PH (1) PH12018501351A1 (en)
RU (1) RU2018126984A (en)
SG (1) SG11201805092WA (en)
WO (1) WO2017112815A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988601C (en) 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3781571B1 (en) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
AU2019374142A1 (en) * 2018-11-01 2021-05-27 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723689C (en) * 2008-05-05 2016-07-05 Ryan A. Shenvi Synthesis of (+) cortistatin a and related compounds
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US20130217014A1 (en) * 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) * 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
JP6494631B2 (en) * 2013-12-24 2019-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Colchistatin analogues and their synthesis and use

Also Published As

Publication number Publication date
JP2019508368A (en) 2019-03-28
AU2016377678A1 (en) 2018-07-12
CN108699085A (en) 2018-10-23
US20180298024A1 (en) 2018-10-18
BR112018012647A2 (en) 2018-12-04
MX2018007804A (en) 2019-07-04
KR20180095051A (en) 2018-08-24
IL260123A (en) 2018-07-31
WO2017112815A1 (en) 2017-06-29
RU2018126984A (en) 2020-01-23
EP3394072A4 (en) 2019-05-29
EA201891511A1 (en) 2018-12-28
CA3009324A1 (en) 2017-06-29
PH12018501351A1 (en) 2019-02-27
EP3394072A1 (en) 2018-10-31
CL2018001733A1 (en) 2018-11-09
CO2018007535A2 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805092WA (en) Cortistatin analogs and uses thereof
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201804363UA (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805001UA (en) Method of treating influenza a
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031